Glenmark Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The product is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB Inc. According to IQVIA sales data for the 12-month period ended April 2026, the Vimpat Injection market recorded annual sales of approximately $15.2 million in the United States.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, ?The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.?

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The company reported a 6,381.9% zoom in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26 over Q4 FY25.

Shares of Glenmark Pharmaceuticals rose 0.18% to Rs 2185.30 on the BSE.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark's Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat?2 Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254].

According to IQVIA? sales data for the 12-month period ending April 2026, the Vimpat? Injection market3 achieved annual sales of approximately $15.2 million.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, ?The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.?

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial. Glenmark's Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial of Fresenius Kabi USA, LLC.

According to IQVIA? sales data for the 12-month period ending March 2026, the Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market2 achieved annual sales of approximately $37.9 million.